BeiGene: Novartis Grabs Tislelizumab Rights
BeiGene's deal with Novartis for PD-1 tislelizumab validates its competitive position, and marks a rising trend of Chinese companies licensing...
420 Views
BeiGene: Cancer Treatment in China--The Underestimated Opportunity
We think that cancer is underdiagnosed and undertreated in China. We analyze the data and propose two approaches for investing in this theme.
521 Views
China Healthcare: Macro Themes
This Insight summarizes the takeaways from a recent China healthcare industry conference.Ā There is much talk of pressures on the industry, but...
635 Views
Jacobio (å ē§ęčÆäø)Ā IPO Trading: Not for the Impatient
The strong cornerstone list helps with the sentiment. However, as the deal is fairly valued, we think there will be little valuation upside based...
636 Views
ECM Weekly (13 December 2020) - Vesync, Sino-Ocean, Jacobio, Netjoy, Sea, Xpeng, NIO, and More!
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
545 Views